No additional risk of colorectal cancer was noted among women treated with aromatase inhibitors (AIs) following a median follow-up of 2.4 and 2.9 years.
Patients with early-stage breast cancer treated with aromatase inhibitors often experience adverse events that lead to discontinuation. In this phase 3 study, researchers sought to determine if duloxetine could manage these symptoms.
Seven interdisciplinary cancer and bone societies released a position statement updating recommendations for limiting bone loss and fracture risk in patients with early-stage breast cancer undergoing treatment with AIs.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Preoperative smoking is associated with increased risk for breast cancer events and distant metastasis in women treated with aromatase inhibitors (AIs). Hampering the utility of AIs, a common treatment for breast cancer, is yet another health risk associated with smoking.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase InhibitorsJune 03, 2016
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
Risk for Fatal Cardiovascular Events Not Increased in Patients With Breast Cancer Taking Aromatase InhibitorsMay 06, 2016
Risk of the most serious cardiovascular events, cardiac ischemia and stroke, were not increased in breast cancer patients taking aromatase inhibitors compared with tamoxifen users.
Breast cancer survivors who are prescribed an adjuvant AI want ongoing communication with their oncology clinician about the potential for arthralgia and how these joint adverse effects can be managed.
Scientists developed a highly sensitive blood test that indicates when breast cancers become resistant to standard hormone treatment. In addition, the test results can be used to guide further treatment.
Cost is a key factor for women to maintain their hormone treatment regimen, researchers report.
Electroacupuncture (EA) produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for patients with early stage breast cancer experiencing joint pain related to the use of aromatase inhibitors to treat breast cancer.
A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?
Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?
A biomarker reflecting expression levels of two genes in tumor tissue has been found to predict which patients may be at risk for late recurrence of estrogen receptor (ER)-positive breast cancer, and when adjuvant letrozole therapy may be of benefit.
Many cancer patients go to the Internet with their questions about side effect management. But the information they glean is from reliable sources—other cancer patients.
Online discussion of side effects associated with aromatase inhibitors is common and often related to drug-switching and discontinuation.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Women who receive aromatase inhibitors for breast cancer after menopause experience very high levels of sexual difficulties, including low interest, insufficient lubrication, and pain with intercourse, according to a recent study.
The anti-estrogen tamoxifen appears to suppress gynecomastia and breast pain in men undergoing androgen-suppression therapy for prostate cancer.
Coadministration of anastrozole (Arimidex) and fulvestrant (Faslodex) improved survival in women with HR-positive metastatic breast cancer.
Overweight women with breast cancer were found to have more estrogen remaining after hormone-suppressing therapy than did women of healthy weight.
Exemestane significantly reduced invasive breast cancer in postmenopausal women at elevated risk, but the aromatase inhibitor also lowered HDL cholesterol levels.
Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.
Breast cancer patients who take estrogen-lowering drugs may avoid having to undergo mastectomy, according to a study to be presented at the Annual Meeting of the American Society of Clinical Oncology.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|